Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.05

EPS Last/This Y

-0.17

EPS This/Next Y

-0.03

Price

0.05

Target Price

Analyst Recom

3.33

Performance Q

-36.7

Relative Volume

Beta

2.39

Ticker: ADAP

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-17	ADAP	0.0549	N/A	N/A	0
2025-11-18	ADAP	0.0549	N/A	N/A	0
2025-11-19	ADAP	0.0549	N/A	N/A	0
2025-11-20	ADAP	0.0549	N/A	N/A	0
2025-11-21	ADAP	0.0549	N/A	N/A	0
2025-11-24	ADAP	0.0549	N/A	N/A	0
2025-11-25	ADAP	0.0549	N/A	N/A	0
2025-11-26	ADAP	0.0549	N/A	N/A	0
2025-12-01	ADAP	0.0549	N/A	N/A	0
2025-12-02	ADAP	0.0549	N/A	N/A	0
2025-12-03	ADAP	0.0549	N/A	N/A	0
2025-12-04	ADAP	0.0549	N/A	N/A	0
2025-12-05	ADAP	0.0549	N/A	N/A	0
2025-12-08	ADAP	0.0549	N/A	N/A	0
2025-12-09	ADAP	0.0549	N/A	N/A	0
2025-12-10	ADAP	0.0549	N/A	N/A	0
2025-12-11	ADAP	0.0549	N/A	N/A	0
2025-12-12	ADAP	0.0549	N/A	N/A	0
2025-12-15	ADAP	0.0549	N/A	N/A	0
2025-12-16	ADAP	0.0549	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

Last Quarter Act. EPS

-0.11

Avg. EPS Est. Current Quarter

-0.12

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

-98.04

Institutional Transactions

Beta

2.39

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.3

Max Drawdown 5-Year %

-99.4

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

-0.66

Average EPS Est. Cur. Y

-0.47

EPS Next Y. (Est.)

-0.5

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

214.2

Return on Equity vs Industry %

227.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

Adaptimmune Therapeutics plc

Sector: Healthcare

Industry: Biotechnology

Employees: 506

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

stock quote shares ADAP – Adaptimmune Therapeutics plc Stock Price stock today

news today ADAP – Adaptimmune Therapeutics plc stock forecast ,stock prediction 2023 2024 2025

marketwatch ADAP – Adaptimmune Therapeutics plc yahoo finance google finance

stock history ADAP – Adaptimmune Therapeutics plc invest stock market

stock prices ADAP premarket after hours

ticker ADAP fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ADAP

No data found

No data found

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y